Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Heparin-induced thrombocytopenia.

P S Becker1, V T Miller

  • 1Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205-2182.

Stroke
|November 1, 1989
PubMed
Summary

Heparin-induced thrombocytopenia (HIT) presents as Type I (common, mild) or Type II (rare, severe). Type II HIT, an immune response, carries significant thromboembolic risks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bortezomib and Vorinostat Therapy as Maintenance Therapy after Autologous Transplant for Multiple Myeloma.

Acta haematologica·2019
Same author

Is there a need for morphologic exam to detect relapse in AML if multi-parameter flow cytometry is employed?

Leukemia·2017
Same author

Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.

Leukemia·2017
Same author

A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation.

Bone marrow transplantation·2016
Same author

A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma.

Blood cancer journal·2016
Same author

A randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCT.

Bone marrow transplantation·2015

Area of Science:

  • Hematology
  • Immunology
  • Pharmacology

Background:

  • Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin therapy.
  • Two distinct types of HIT exist, differing in etiology, clinical presentation, and prognosis.

Purpose of the Study:

  • To differentiate between Type I and Type II heparin-induced thrombocytopenia.
  • To highlight the distinct mechanisms and clinical implications of each HIT type.

Main Methods:

  • Clinical observation and analysis of patient data differentiating HIT types.
  • Review of immunological mechanisms underlying platelet aggregation in HIT.

Main Results:

  • Type I HIT: common, early onset, direct platelet aggregation, mild, benign, rare thromboembolism.
  • Type II HIT: infrequent, late onset, immune-mediated (IgG/IgM), severe, associated with significant thromboembolic events (stroke, white clots).

Conclusions:

  • Understanding the differences between Type I and Type II HIT is crucial for appropriate patient management.
  • Type II HIT requires prompt recognition and management due to its severe, potentially life-threatening thromboembolic complications.

Related Experiment Videos